Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk commits to gender equality

This article was originally published in Scrip

Executive Summary

Novo Nordiskis helping to achieve the United Nations' Millennium Development Goal number 3: to empower women and promote gender equality. The company says that it will help women with diabetes in the developing world through improving the prevention, diagnosis and treatment of the condition. "Women have a higher diabetes-related morbidity and mortality due to biological, cultural and socioeconomic factors … women are often at a disadvantage getting diagnosed and receiving proper treatment," said Lise Kingo, the company's executive vice-president. Novo Nordisk will also co-host a forum on Women, Diabetes and Development in New York alongside the World Diabetes Foundation and the Global Alliance for Women's Health on September 24th.

You may also be interested in...

Joint Tendering Creates ‘Attractive Nordic Market’

Joint tendering among Nordic countries can help reduce shortages of older, off-patent medicines. 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Scotland Recommends Interim Funding For Regeneron/Sanofi’s Libtayo

Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts